Clinical Study
Central Precocious Puberty: Treatment with Triptorelin 11.25 mg
Table 1
Clinical data at the beginning of GnRH analog treatment (M0) and after 12 months of quarterly triptorelin 11.25 mg (M12).
| | M0 | M12 |
| Bone age, years | | | Height, cm | | | Height, SDS* | | | Growth velocity, cm/year | | | Predicted adult height, cm | | | Predicted adult Height, SDS | | | Body mass index, kg/m2 | | | Body mass index, SDS | | | Midparental height, cm | | Midparental height, SDS | |
|
|
*SDS for bone age; versus M0; versus M0.
|